Eli Lilly & Co. is solidifying its leadership in the obesity treatment sector, buoyed by strong sales forecasts for its weight-loss drugs, including Zepbound and Mounjaro, following a successful fourth quarter. Despite facing intensified competition from Novo Nordisk and emerging alternatives like Hims & Hers, Eli Lilly has seen its share price rise significantly, bolstered by analyst upgrades and favorable market conditions. Additionally, the company is expected to launch a new oral weight-loss medication and strengthen its market position through government-backed pricing agreements that could enhance patient access.
“It’s been losing ground to US archrival Eli Lilly & Co. — which started selling its Zepbound weight-loss drug in late 2023.”
“Eli Lilly (LLY) stock rose as much as 7% early Wednesday after the pharmaceutical giant rolled out a strong sales outlook, touting the strength of its weight loss portfolio and pressuring shares of Danish drugmaker Novo Nordisk (NVO) for a second-straight day.”
“Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill.”
“$LLY is up over 8% after a Q4 earnings beat and raised 2026 outlook”
“Eli Lilly provides an upbeat sales forecast for the year as strong demand for its weight loss drug cemented its position at the top of the obesity market”
“We're the market leaders in both diabetes and obesity now, says Eli Lilly CEO David Ricks on the company’s Q4 results.”
“Throughout 2025, the CNBC TV host praised the company, not only for its weight loss drug but also for its manufacturing capacity and drug pipeline.”
“Goldman Sachs was out with an optimistic note for the firm in early February as it raised the share price target to $1,260 from $1,145 and kept a Buy rating on the shares.”
“Like Goldman, JPMorgan also raised the share price target in February. It bumped the target up to $1,300 from $1,150 and kept an Overweight rating on the stock.”
“The bank commented that the pharmaceutical company has growth potential due to its presence in the phase diabetes and obesity markets.”
“Innovent Biologics on Sunday said it signed a deal with Eli Lilly to jointly develop experimental medicines targeting cancer and immune-related diseases, extending a partnership that has spanned more than a decade.”
“Lilly will hold exclusive rights to develop and commercialize the resulting medicines outside Greater China, while Innovent will retain rights in the region.”
